NeoGenomics announces Medicare coverage for RaDaR assay

NeoGenomics announced that the Molecular Diagnostics Services Program has conveyed coverage for the RaDaR assay, a personalized liquid biopsy for minimal residual disease and recurrence detection. Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for fee-for-service Medicare patients within the United States with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The coverage includes patients with a personal history of high-risk stage II/III HR+/HER2- breast cancer, five or more years from diagnosis who presently do not have evidence of disease. NeoGenomics’ tumor informed RaDaR assay has been designed to detect extremely low levels of circulating tumor DNA in the blood with exceptional sensitivity and specificity. RaDaR can monitor up to 48 tumor-specific variants unique to each patient’s tumor, giving patients additional time and information for important treatment management decisions.